Physician profile
Matthew J Schear
NPI 1417354010
$2,014.59
in general payments reported to CMS, 2019-2025
13 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $173 · 2021: $320 · 2022: $202 · 2023: $429 · 2024: $224 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.79 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $501.22 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $439.89 | 2020-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $282.47 | 2019-2023 | |
| Alcon Vision LLC | $147.04 | 2021-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Allergan, INC. | $128.28 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $114.54 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $102.70 | 2020-2021 | |
| Abbvie INC. | $96.99 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Biotissue Holdings INC. | $71.22 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $47.98 | 2023 | Tecnis Simplicity |
| Amgen INC. | $36.69 | 2025 | Tepezza |
| Sight Sciences, INC. | $28.23 | 2022 | |
| Rayner Intraocular Lenses Limited | $17.34 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Schear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.